[{"id":"e5c5e3c9-2ffb-460f-a19f-d1731cde39ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT03897036","created_at":"2021-01-18T19:11:35.946Z","updated_at":"2024-07-02T16:35:50.335Z","phase":"Phase 1","brief_title":"Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)","source_id_and_acronym":"NCT03897036","lead_sponsor":"Senhwa Biosciences, Inc.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e silmitasertib (CX-4945)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-04-18"}]